---
schema_version: "secwatch.filing_event.v1"
accession: "0001534120-25-000011"
form_type: "8-K"
ticker: "AVTX"
cik: "0001534120"
company_name: "Avalo Therapeutics, Inc."
filed_at: "2025-10-10T23:59:59+00:00"
generated_at: "2026-05-17T04:04:23.475215+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "medium"
source: SEC EDGAR
---

# Avalo Therapeutics posts updated investor presentation; no material new data disclosed

## Summary
- Presentation dated October 2025 describes pipeline of novel IL-1β therapies.
- No new clinical data, financial results, or guidance changes included in update.
- Presentation used for routine investor meetings; no material events announced.

## SEC filing metadata
- accession: 0001534120-25-000011
- form_type: 8-K
- ticker: AVTX
- cik: 0001534120
- company_name: Avalo Therapeutics, Inc.
- filed_at: 2025-10-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: medium
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000011/0001534120-25-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534120/000153412025000011/avtx-20251010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001534120-25-000011
- JSON: https://secwatch.observer/filing/0001534120-25-000011.json
- Plain text: https://secwatch.observer/filing/0001534120-25-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.